Research and Markets: 2007 Trial TRAX - Alzheimer's Disease - Clinical Trial Monitoring Brief Provides Detailed Compilations And Analysis Of Ongoing Studies
Posted on: Thursday, 4 October 2007, 12:00 CDT
Research and Markets (http://www.researchandmarkets.com/reports/c70521) has announced the addition of Trial TRAX - Alzheimer's Disease - Clinical Trial Monitoring Brief to their offering.
The main body of the brief presents key data points from competitor clinical trials in a matrix format, enabling decision-makers the ability to quickly recall and analyze information on competitor studies. The brief's reference-guide format is designed to provide decision makers with easy access to key intelligence on competitive clinical development programs. Primary data points include:
- Study Drug
- Mechanism of Action
- Company-Sponsor
- Phase of Development
- Number of Patients
- Study Design
- Primary Endpoints
- Study Start Date
Clients utilize the Trial TRAX briefing reports to:
- Monitor clinical development programs of competitors
- Quickly evaluate depth and breadth of competitive landscape
- Easy-to-use reference guide for analyzing competitor clinical trials
- Identify potential patient recruitment challenges
- Benchmark competitor clinical trial designs
The Trial TRAX Clinical Intelligence Monitoring series provides detailed compilations and analysis of ongoing clinical studies within a specific therapeutic area or indication. Additionally, the Trial TRAX briefs contain synthesized background information on the profiled-disease; typically includes top-line information on:
- Epidemiology
- Patient Segmentation
- Clinical endpoints
The Trial TRAX brief also contains analysis of the clinical landscape with assessments including:
- % utilization of key clinical endpoints
- Number of ongoing trials (by phase of development)
- Key companies sponsoring clinical trials
Content Outline:
Section 1: Executive Summary
Alzheimer's Disease Overview: Background, Epidemiology
Alzheimer's Disease Overview: Etiology & Disease Staging
Treatments for Alzheimer's Disease
Historical Sales of Market Alzheimer's Disease Therapeutics
Clinical Endpoints in Alzheimer's Disease Trials
Overview of Clinical Landscape
Key Players in Alzheimer's Disease
Section 2: Ongoing Clinical Trial in Alzheimer's Disease
Competitive Clinical Trial Details
Section 3: Appendix
Disclaimer
Report Licensing
Companies Mentioned:
- Eli Lilly
- GlaxoSmithKline
- Merck
- Novartis
- Pfizer
- Wyeth
For more information visit http://www.researchandmarkets.com/reports/c70521.
Source: Business Wire
Related Articles
- Reportlinker Adds Innovations and Trends in Clinical Trials: Microdosing (Phase 0 Trials), Adaptive Trials, Phase IV Trials and the Role of Information Technology
- Resverlogix RVX-208 Second Clinical Trial Demonstrates Success on Key Reverse Cholesterol Transport Markers
- Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
- Bapineuzumab To Become the First-to-Market Disease-Modifying Alzheimer's Drug After Flurizan's Discontinuation
- $4 Trillion in Cost Savings to U.S. From New Disease-Modifying Alzheimer's Treatments
- Vicor Technologies Initiates Clinical Sites for Pivotal Vital Trial; Enrolls First Two Patients; Targets FDA 510(K) Submission in 2008
- Largest-Ever Alzheimer's Drug Trial Begins
- Largest Alzheimer's Drug Trial Launched
- Naproxen and Celecoxib Suspended in Alzheimer Prevention Trial
- Alzheimer's Drug Fails Key Test, Myriad Says
 |
 |
User Comments (0)
RSS Feeds